GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actelion Ltd (OTCPK:ALIOF) » Definitions » Total Payout Ratio

Actelion (Actelion) Total Payout Ratio : 0.64 (As of May. 05, 2024)


View and export this data going back to . Start your Free Trial

What is Actelion Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Actelion's current Total Payout Ratio is 0.64.


Actelion Total Payout Ratio Historical Data

The historical data trend for Actelion's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actelion Total Payout Ratio Chart

Actelion Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Total Payout Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.11 0.70 0.73 2.15 1.13

Actelion Quarterly Data
Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17
Total Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.56 0.71 1.23 1.08 -0.36

Competitive Comparison of Actelion's Total Payout Ratio

For the Biotechnology subindustry, Actelion's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Actelion's Total Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actelion's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Actelion's Total Payout Ratio falls into.



Actelion Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Actelion's Total Payout Ratio for the fiscal year that ended in Dec. 2016 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (-650.35 + 38.516 + -155.496) / 681.612
=1.13

Actelion's Total Payout Ratio for the quarter that ended in Mar. 2017 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (-0.76 + 71.834 + 0) / 196.341
=-0.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Actelion Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of Actelion's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Actelion (Actelion) Business Description

Traded in Other Exchanges
N/A
Address
Actelion is a Swiss biopharmaceutical firm with several products on the market, largely focused on pulmonary arterial hypertension: Tracleer, Opsumit, Uptravi, Ventavis, and Veletri treat various stages of the disease via different methods of administration. Zavesca is a second-line option for Gaucher disease, and Valchlor treats a rare form of blood cancer. Actelion has created a global commercial infrastructure for its approved orphan drugs and has supplemented its internal pipeline through in-licensing and acquisitions.

Actelion (Actelion) Headlines

From GuruFocus

Actelion Still On Growth Track

By reports.droy reports.droy 02-18-2015

Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary

By Holly LaFon Holly LaFon 01-24-2017

Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary

By Holly LaFon Holly LaFon 02-14-2017

Jean Hynes Reduces Stake in Actelion

By Kyle Ferguson Kyle Ferguson 08-03-2016